Abstract:In clinical trials, patients sometimes discontinue study treatments prematurely due to reasons such as adverse events. Treatment discontinuation occurs after the randomisation as an intercurrent event, making causal inference more challenging. The Intention-To-Treat (ITT) analysis provides valid causal estimates of the effect of treatment assignment; still, it does not take into account whether or not patients had to discontinue the treatment prematurely. We propose to deal with the problem of treatment discontinuation using principal stratification, recognised in the ICH E9(R1) addendum as a strategy for handling intercurrent events. Under this approach, we can decompose the overall ITT effect into principal causal effects for groups of patients defined by their potential discontinuation behaviour in continuous time. In this framework, we must consider that discontinuation happening in continuous time generates an infinite number of principal strata and that discontinuation time is not defined for patients who would never discontinue. An additional complication is that discontinuation time and time-to-event outcomes are subject to administrative censoring. We employ a flexible model-based Bayesian approach to deal with such complications. We apply the Bayesian principal stratification framework to analyse synthetic data based on a recent RCT in Oncology, aiming to assess the causal effects of a new investigational drug combined with standard of care vs. standard of care alone on progression-free survival. We simulate data under different assumptions that reflect real situations where patients' behaviour depends on critical baseline covariates. Finally, we highlight how such an approach makes it straightforward to characterise patients' discontinuation behaviour with respect to the available covariates with the help of a simulation study.

Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials with Time-to-Event Outcomes under ICH E9 (R1)

Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation due to adverse events

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation

Time-to-event estimands and loss to follow-up in oncology in light of the estimands framework

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance

Estimating treatment effect in randomized trial after control to treatment crossover using external controls

Causal Inference for Time-to-event Data with a Cured Subpopulation.

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Incremental Causal Effect for Time to Treatment Initialization

Estimating the Causal Effects in Randomized Trials for Survival Data with A Cure Fraction and Non Compliance

Implementation of ICH E9 (R1): a few points learned during the COVID-19 pandemic

Defining estimands in clinical trials: A unified procedure

Defining estimands using a mix of strategies to handle intercurrent events in clinical trials

11. Identification and Estimation of Causal Effects with Time-Varying Treatments and Time-Varying Outcomes

Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial

Estimating Time-Varying Direct and Indirect Causal Excursion Effects with Longitudinal Binary Outcomes

Translating questions to estimands in randomized clinical trials with intercurrent events

The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies

Estimation of treatment effect among treatment responders with a time‐to‐event endpoint